SCHEMBL1592988

SCHEMBL1592988

CCOc1nn(Cc2ccc(OC)cc2)c2ncc(NC(=O)O)cc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ NR3C1 P04150 5/20 0.43
▸ POLB P06746 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ MAPT P10636 4/20 0.42
▸ PDE4B Q07343 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ PKM P14618 1/20 0.40
▸ PDE1B Q01064 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592875 0.93 NR3C1 (0.45) MEN1KMT2AHSD17B10HPGDNR3C1
SCHEMBL1593157 0.88 MEN1 (0.44) MEN1KMT2AHSD17B10HPGDNR3C1
SCHEMBL1593855 0.80 PTGDR2 (0.44) MEN1KMT2AHSD17B10HPGDNR3C1
SCHEMBL1593142 0.80 CNR1 (0.47) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL1592961 0.80 PDE1B (0.53) KMT2AHSD17B10HPGDPOLBRXFP1
SCHEMBL19349345 0.77 RET (0.42) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL28431943 0.77 PDE1B (0.49) MEN1KMT2APOLBCNR1CNR2
SCHEMBL28431878 0.76 CNR1 (0.47) HSD17B10HPGDCNR1CNR2MAPT
SCHEMBL28425625 0.76 PDE1B (0.48) MEN1KMT2ACNR1CNR2ALDH1A1
SCHEMBL1593041 0.76 BRAF (0.61) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394795-B2 Pyrazole [3, 4-B] pyridine Raf inhibitors ARRAY BIOPHARMA INC. (US) 2013-03-12 — — US disclosed
EP-2265610-B1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-12-12 — — EP disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 — — US disclosed
EP-2265610-A1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 — — EP disclosed
WO-2009111279-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS BRAF, RAF1, ARAF MEN1 1680/4885KMT2A 3704/4885HSD17B10 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback